vertex pharmaceuticals - Search News

Vertex Pharma drops

The Boston Globe · 9h

Vertex’s non-opioid pain drug gets some UnitedHealth coverage

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Seeking Alpha on MSN · 10h

Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two commercial formularies.

BioPharma Dive · 6h

Vertex’s new pain drug gets first coverage nod from major insurer

Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an interim decision while a formal review continues.

Investing.com India · 11h

UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher cost - Bloomberg

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to Bloomberg News. However, the drug has been assigned to a costlier tier compared to other pain treatments on UnitedHealth’s approved drug lists.

7h

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

The stock's fall snapped a four-day winning streak.

16h

Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Barchart on MSN1d

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

1d

Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market

Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...

BioPharma Dive14h

Tris to ask for approval of dual-acting pain drug

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

23h

Zacks Research Issues Pessimistic Outlook for VRTX Earnings

Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...

22h

Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results